Call Now Open

Oxford-Harrington Rare Disease Scholar Award

You've just added:

Home / News

Press Releases

February 06, 2024

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading

January 03, 2024

Jonathan Stamler, MD, Named Fellow of the 2023 National Academy of Inventors

Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading

December 21, 2023

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading

November 30, 2023

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading

October 25, 2023

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Dis

ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading

October 04, 2023

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading

October 03, 2023

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years. Continue Reading

September 23, 2023

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

Agreement enables the development of therapeutics, including AcuraStem's AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase Continue Reading

September 14, 2023

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC) Continue Reading

July 05, 2023

Takeda Licenses LSU Health New Orleans Technology for Potential Rare Neurological Disorders

New Orleans, LA – LSU Health New Orleans today announced that has exercised its option to receive an exclusive license to certain early-stage technology designed to slow the progression of DNA repeat expansion disorders.In DNA repeat expansion disorders, a segment of repeated DNA expands within a gene to cause disease. The... Continue Reading